Eli Lilly state of matter II psoriasis study meets primary endpoint Pharmaceutical business concern Review Eli Lilly and Company has reported that its Anti-IL-17 monoclonal antibody, Ixekizumab, met primary termination in Phase II examination in patients with degenerative plaque psoriasis . The study reported that significantly more patients achieved At least a 75% ... Link To Article
No comments:
Post a Comment